Gilead Sciences, Inc. $GILD Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,184 shares of the biopharmaceutical company’s stock after selling 1,721 shares during the quarter. Freedom Investment Management Inc.’s holdings in Gilead Sciences were worth $1,905,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Southland Equity Partners LLC lifted its holdings in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 92 shares in the last quarter. Twelve Points Wealth Management LLC lifted its holdings in Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after buying an additional 98 shares in the last quarter. Argentarii LLC lifted its holdings in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 99 shares in the last quarter. Lodestar Private Asset Management LLC lifted its holdings in Gilead Sciences by 3.6% in the 1st quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 100 shares in the last quarter. Finally, Advantage Trust Co lifted its holdings in Gilead Sciences by 13.6% in the 2nd quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $121.46 on Thursday. The firm has a market cap of $150.71 billion, a PE ratio of 24.20, a price-to-earnings-growth ratio of 0.85 and a beta of 0.34. The firm’s 50-day simple moving average is $115.38 and its 200-day simple moving average is $110.78. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider directly owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,500 shares of company stock valued at $8,281,540 in the last quarter. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. Finally, Rothschild & Co Redburn upped their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $121.14.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.